EGE presents opinion on ethical aspects of nanomedicine to EU Commission

5 February 2007

Following the request made by European Commission President Jose Manuel Barroso on November 10, 2005, the European Group on Ethics in Science and New Technologies (EGE), chaired by Swedish philosopher Goran Hermeren, has now handed the President its opinion on the ethical aspects of nanomedicine.

In its Opinion, the EGE acknowledges that nanomedicine offers the possibility of new diagnostic, treatment and preventive methods that may open up promising areas of medicine. The Opinion focuses on ethics issues arising from nanomedicine but also discusses a number of problems raised by nanotechnology insofar as they concern primarily health-related issues.

Safety issues paramount

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight